We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

64 hedge funds and large institutions have $18.5M invested in NeuBase Therapeutics, Inc. Common Stock in 2015 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 20 increasing their positions, 11 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

193% more call options, than puts

Call options by funds: $2.55M | Put options by funds: $871K

109% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 11

82% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 11

21% more funds holding

Funds holding: 53 → 64 (+11)

64% less capital invested

Capital invested by funds: $51.1M → $18.5M (-$32.6M)

Holders
64
Holders Change
+11
Holders Change %
+20.75%
% of All Funds
1.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
20
Reduced
11
Closed
11
Calls
$2.55M
Puts
$871K
Net Calls
+$1.68M
Net Calls Change
+$1.19M

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$14.7M
2
BBA
Baker Bros. Advisors
New York
+$3.06M
3
TI
Turner Investments
Pennsylvania
+$2.36M
4
KCM
Knoll Capital Management
Florida
+$1.69M
5
SFM
Sphera Funds Management
Israel
+$1.55M

Top Sellers

Rank Fund Capital Flow
1
VAM
Visium Asset Management
New York
-$8.62M
2
Millennium Management
Millennium Management
New York
-$5.95M
3
VM
VHCP Management
New York
-$3.98M
4
LOAMU
Lombard Odier Asset Management (USA)
New York
-$3.78M
5
KCM
Kennedy Capital Management
Missouri
-$1.08M

NBSE Hedge Fund Activity: Q1 2015 in Review

64 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q1 2015, worth a combined $18.5M — down 64% from $51.1M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new NBSE positions and 11 closed out — a net gain of 12 holders — while 20 added to existing stakes and 11 trimmed.

The largest buyer was Broadfin Capital, opening a new position worth an estimated $14.7M. The largest seller was Visium Asset Management, exiting entirely with an estimated $8.62M sold.

  • 64 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q1 2015, up from 53 in Q4 2014.
  • Funds reported $18.5M of NeuBase Therapeutics, Inc. Common Stock stock for Q1 2015, down 64% quarter-over-quarter.
  • 23 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q1 2015 and 11 closed out, a net change of +12 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q1 2015 was Broadfin Capital, an estimated $14.7M added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q1 2015 was Visium Asset Management, an estimated $8.62M sold.

Based on aggregated 13F filings for Q1 2015.